Neurochemical investigations of Tourette's syndrome (TS) suggest that the symptoms of this disorder may be the result of an imbalance among several neurotransmitter and/or neuromodulator systems. Neurochemicals which have been studied included: catecholamines; acetylcholine; tryptophan and its metabolites; the amino acids γ-aminobutyric acid (GABA), glutamate, phenylalanine and p-tyrosine; trace amines; opioid peptides; cyclic AMP and androgenic hormones. A suitable animal model of TS would do much to advance our understanding of this disorder, and there are some interesting recent developments in this regard.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th edn (DSM-IV), American Psychiatric Association , Washington, DC
2.
Anderson G.M., Pollak E.S., Chatterjee D., Leckman J.F., Riddle M.A., Cohen D.J. (1992) Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 123-133
3.
Ang A., Borison R., Dysken M., Davis J.M. (1982) Reduced excretion of MHPG in Tourette's syndrome . In Friedhoff A H, Chase T N (eds), Advances in neurology, Vol. 35. Raven Press, NY , pp. 171-175
4.
Asnis G.M., Wetzler S., Sanderson W.C., Kahn R.S., van Praag H.M. (1992) Functional interrelationship of serotonin and norepinephrine: cortisol responses to mCPP and desipramine in patients with panic disorder, patients with depression and normal control subjects. Psychiatr Res43: 65-76
5.
Baker G.B., Bornstein R.A., Douglass A.B., Carroll A., King G. ( 1991a) Urinary excretion of metabolites of norepinephrine in Tourette's syndrome. Mol Chem Neuropathol13: 225-232
Baker G.B., Bornstein R.A., Douglass A.B., van Muyden J.C., Ashton S., Bazylewich T-L. (1993) Urinary excretion of MHPG and normetanephrine in attention deficit hyperactivity disorder. Mol Chem Neuropathol18: 173-178
9.
Bornstein R.A., Baker G.B. (1990) Urinary amines in Tourette's syndrome patients with and without phenylethylamine abnormality. Psychiatr Res31: 279-286
10.
Bornstein R.A., Baker G.B. (1991) Neuropsychological performance and urinary phenylethylamine in Tourette's syndrome. J Neuropsychiatr Clin Neurosci3: 417-421
11.
Bornstein R.A., Baker G.B. (1992a) Urinary indoleamines in Tourette syndrome patients with obsessive-compulsive characteristics. Psychiatr Res41: 267-274
12.
Bornstein R.A., Baker G.B. (1992b) Urinary amines in adults with Tourette's syndrome . Psychiatr Res43: 277-285
13.
Bornstein R.A., Baker G.B., Carroll A., King G., Ashton S. (1990) Phenylethylamine metabolism in Tourette's syndrome . J Neuropsychiatr Clin Neurosci2: 408-412
14.
Boulton A.A., Juorio A.V. (1982) Brain trace amines. In Lajtha A (ed.), Handbook of neurochemistry. Plenum Publishing Corp, NY, pp. 189-222
15.
Brett P., Robertson M., Gurling H. (1993) Failure to find linkage and increased homozygosity for the dopamine D3 receptor gene in Tourette's syndrome. Lancet341: 1225
16.
Brett P.M., Curtis D., Robertson M.M., Gurling H M D (1995) Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior . Am J Psychiatr152: 437-440
17.
Brooks D.J., Turjanski N., Sawle G.V., Playford E.D., Lees A.J. (1992) PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 227-232
18.
Brunn R.D. (1984) Gilles de la Tourette's syndrome: an overview of clinical experience. J Am Acad Child Psychiatr23: 126-133
Cassel D., Selinger Z. (1978) Mechanisms of adenylate cyclase activation through the β-adrenergic receptor: catecholamine-induced displacement of bound GDP by GTP. Proc Natl Acad Sci USA75: 4155-4159
21.
Chappell P.B. (1994) Commentary on sequential use of opioid antagonists and agonists in Tourette's syndrome. Lancet343: 556
22.
Chappell P.B., Leckman J.F., Riddle M.A., Anderson G.M., Listwack S.J., Ort S.I., Hardin M.T., Scahill L.D., Cohen D.J. (1992) Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 253-262
23.
Chappell P.B., Leckman J.F., Scahill L.D., Hardin M.T., Anderson G., Cohen D.J. (1993) Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatr Res47: 267-280
24.
Chokka P.R., Baker G.B., Bornstein R.A., de Groot C.M. (1995) The biochemistry of Tourette's syndrome. Metab Brain Dis (in press)
25.
Cohen B.J., Shaywitz B.A., Caparulo B.K., Young J.G., Bowers M.B. Jr (1978) Chronic multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. Arch Gen Psychiatr35: 245-250
26.
Cohen D.J., Shaywitz B.A., Young J.C., Carbonari C.M., Nathanson J.A., Lieberman D., Bowers M.B., Maas J.W. (1979) Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette. J Am Acad Child Psychiatr18: 320-341
27.
Comings D.E. (1990a) Blood serotonin and tryptophan in Tourette syndrome . Am J Med Genet36: 418-430
28.
Comings D.E. (1990b) Tourette syndrome and human behavior. Hope Press, Duarte, CA
29.
Comings D.E., Muhleman D., Dietz G., Dino M., LeGro R, Gade R. (1993a) Association between Tourette's syndrome and homozygosity at the dopamine D3 receptor gene. Lancet341: 906
30.
Comings D.E., Muhleman D., Dietz G., Dino M., LeGro R., Gade R. ( 1993b) Authors' reply. Lancet341: 1483-1484
31.
Cooper D M F, Londos C., Gill D.L., Rodbell M. (1982) Opiate receptor-mediated inhibition of adenylate cyclase in rat striatal plasma membrane. J Neurochem38: 1164-1167
32.
de Groot C.M., Bornstein R.A., Baker G.B. (1995) Obsessive-compulsive symptom clusters and urinary amine correlates in Tourette syndrome. J Nerv Ment Dis183: 224-230
Di Chiara G., Morelli M., Consolo S. (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci17: 228-233
35.
Dimitsopulos T., Kurlan R. (1993) Tourette's syndrome and nicotine withdrawal. J Neuropsychiatr5: 108-109
36.
Dingledine R., McBain C.J. (1994) Excitatory amino acid transmitters. In Siegel G J, Agranoff B W , Albers R W, Molinoff P B (eds), Basic neurochemistry. 5th Edn, Raven Press, NY, pp.367-387
37.
Dodick D., Adler C.H. (1992) Tourette's syndrome: current approaches to recognition and management. Postgrad Med92: 299-308
38.
Done C J G, Sharp T. (1992) Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol107: 240-245
Dursun S.M., Handley S.L. (1994) Complex of rapid movements and vocalization induced by RX336-M in mice: possible relevance to Tourette's syndrome. J Psychopharmacol8: 27-31
41.
Eiring A., Manier D.H., Bieck P.R., Howells R.D., Sulser F. (1992) The serontonin/norepinephrine link beyond the β-adrenoceptor . Mol Brain Res16: 211-214
42.
Elia J. ( 1993) Drug treatment for hyperactive children. Therapeutic guidelines. Drugs46: 863-871
43.
Fang J., Yu P.H., Gorrod G.W., Boulton A.A. (1995) Inhibition of monoamine oxidase by metabolites of haloperidol: possible cause of depressed monoamine oxidase activity in schizophrenic patients. Psychopharmacology (in press)
44.
Faraj B.A., Olkowski Z.L., Jackson R.T. (1994) Active 3H-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. Pharmacology48: 320-327
45.
Frankel M., Cummings J.L., Robertson M.M., Trimble M.R., Hill M.A., Benson D.F. (1986) Obsessions and compulsions in Gilles de la Tourette's syndrome. Neurology36: 378-382
46.
Freed W.J. (1994) Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects. Neurosci Biobehav Rev18: 111-120
47.
Gelernter J., Kennedy J.L., Grandy D.K., Zhou Q.Y., Civelli O., Pauls D.L., Pakstis A., Kurlan R., Sunahara R.K., Niznik H.B., Odowd B., Seeman P., Kidd K.K. (1993) Exclusion of close linkage of Tourette's syndrome to D1-dopamine receptor. Am J Psychiatr150: 449-453
48.
Gelernter J., Pauls D.L., Leckman J., Kidd K.K., Kurlan R. (1994) D2 dopamine receptor alleles do not influence severity of Tourette's syndrome—results from four large kindreds . Arch Neurol51: 397-400
49.
George M.S., Trimble M.R., Ring H.A., Sallee F.R., Robertson M.M. (1993a) Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. Am J Psychiatr150: 93-97
50.
George M.S., Trimble M.R., Robertson M.M. (1993b) Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Hum Psychopharmacol8: 327-334
51.
Goetz C.G. (1992) Clonidine and clonazepam in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press. NY, pp. 245-251
52.
Golden G.S. (1988) The relationship between stimulant medication and tics. Pediatr Ann17: 405-408
53.
Haber S.N., Wolfer D. (1992) Basal ganglia peptidergic staining in Tourette syndrome: a follow-up study. In Chase T N , Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY , pp. 145-150
54.
Handley S.L., Dursun S.M. (1992) Serotonin and Tourette's syndrome: movements such as head-shakes and wet-dog shakes may model human tics. Adv Biosci85: 235-253
55.
Handley S.L., Miskin R.C. (1977) The interaction of some kynurenine pathway metabolites with 5-hydroxytryptophan and 5-hydroxytryptamine. Psychopharmacology51: 305-309
56.
Harcherick D.F., Leckman J.F., Detlor J., Cohen D.J. (1984) A new instrument for clinical studies of Tourette's syndrome. J Am Acad Child Psychiatr23: 153-166
57.
Hebebrand J., Nöthen M.M., Lehm Kuhl G., Poustka F., Schmidt M., Propping P., Remschmidt H. (1993) Tourette's syndrome and homozygosity for the dopamine D3 receptor gene. Lancet341: 1483
58.
Henderson M.G., Perry K.W., Fuller R.W. (1993) Possible involvement of dopamine in the long-term serotonin depletion by p-chloroamphetamine and β,β-difluoro-p-chloroamphetamine in rats. J Pharmacol Exp Ther267: 417-424
59.
Hewlett WA (1993) The use of benzodiazepines in obsessive compulsive disorder and Tourette's syndrome. Psychiatr Ann23: 309-316
60.
Huang X.M., Nichols D.E. (1993) 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol238: 291-296
61.
Insel T.R. (1992) Toward a neuroanatomy of obsessive-compulsive disorder . Arch Gen Psychiatr49: 739-744
62.
Jankovic J. (1993) Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol50: 286-288
63.
Juorio A.V. (1982) The effects of some antipsychotic drugs, D-amphetamine and reserpine on the concentration and rate of accumulation of tryptamine and 5-hydroxytryptamine in the mouse striatum. Can J Physiol Pharmacol60: 376-380
64.
Juorio A.V., Paterson I.A. (1990) Tryptamine may couple dopaminergic and serotonergic transmission in the brain. Gen Pharmacol5: 613-616
65.
Kaiser C., Jain T. ( 1985) Dopamine receptors: functions, subtypes and emerging concepts . Med Res Rev5: 145-229
66.
Kaplan H.I., Sadock B.J., Grebb J.A. (1994) Tic disorders. In Kaplan and Sadock's synopsis of psychiatry. 7th edn, Willams & Wilkins, Baltimore, MD, pp. 1080-1087
67.
Klawans H.L., Falk D.K., Nausieda P.A., Weiner W.J. (1978) Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology28: 1064-1066
68.
Koslow S.H., Cross C.K. (1982) Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implications. In Friedhoff A J, Chase T N (eds), Advances in neurology, Vol. 35. Raven Press, NY, pp. 185-197
69.
Kurlan R., Majumdar L., Deeley C., Mudholkar G.S., Plumb S., Como P.G. (1991) A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol30: 19-23
70.
Leckman J.F., Scahill L. (1990) Possible exacerbation of tics by androgenic steroids (letter). New Engl J Med322: 1674
71.
Leckman J.F., Detlor J., Harcherik D.F., Young J.G., Anderson G.M., Shaywitz B.A., Cohen D.J. (1983) Acute and chronic clonidine treatment in Tourette's syndrome: a preliminary report on clinical response and effect on plasma and urinary catecholamine metabolites, growth hormone and blood pressure. J Am Acad Child Psychiatr22: 433-440
72.
Leckman J.F., Riddle M.A., Berrettini W.H., Anderson G.M., Hardin M., Chappell P., Bissette G., Nemeroff C.B., Goodman W.K., Cohen D.J. (1988) Elevated CSF dynorphan A [1-8] in Tourette's syndrome . Life Sci43: 2015-2023
73.
Leckman J.F., Hardin M.T., Riddle M.A., Stevenson J., Ort S.I., Cohen D.J. (1991) Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatr48: 324-328
74.
Leckman J.F., Pauls D.L., Peterson B.S., Riddle M.A., Anderson G.M., Cohen D. (1992) Pathogenesis of Tourette syndrome: clues from the clinical phenotype and natural history. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 15-24
75.
Leckman J.F., Goodman W.K., Anderson G.M., Riddle M.A., Chappell P.B., McSwiggan-Hardin M.T., McDougle C.J., Scahill L.D., Ort S.I., Pauls D.L., Cohen D.J., Price L.H. (1995) Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome and healthy controls. Neuropsychopharmacology12: 73-86
76.
LeWitt P. A (1992) Therapeutics of Tourette syndrome: new medication approaches. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp.263-270
77.
Li S., Sivan S.P., Hong J.S. (1986) Regulation of the concentration of dynorphin A1-8 in the striatonigral pathway by the dopaminergic system. Brain Res398: 390-392
78.
Lichter D., Majumdar L., Kurlan R. (1988) Opiate withdrawal unmasks Tourette's syndrome. Clin Neuropharmacol11: 559-564
Manier D.H., Gillespie D.D., Sanders-Bush E., Sulser F. (1987) The serotonin/noradrenaline-link in brain. I. The role of noradrenaline and serotonin in the regulation of density and function of β-adrenoceptors and its alteration by desipramine. Naunyn-Schmiedebergs Arch Pharmacol335: 109-114
81.
Marti-Masso J.F., Obeso J.A. (1985) Coprolalia associated with hemiballismus: response to tetrabenazine. Clin Neuropharmacol8: 189-190
82.
Martin L.L., Baker G.B., Wood P.L. (1988) Tryptamine turnover: effects of drugs. In Boulton A A, Juorio A V, Downer R G H (eds), Trace amines: comparative and clinical neurobiology. Humana Press, Clifton, NJ, pp. 95-104
83.
McConville B.J., Norman A.B., Fogelson M.H., Erenberg G. (1994) Sequential use of opioid antagonists and agonists in Tourette's syndrome. Lancet343: 601
84.
McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.D. (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatr51: 302-308
85.
Mercugliano M. (1993) Psychopharmacology in children with developmental disabilities. Pediatr Clin North Am40: 593-616
86.
Merikangas J.R., Merikangas K.R., Kopp U., Hanin I. (1985) Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta Psychiatr Scand72: 395-399
87.
Messiha F.S. (1988) Biochemical pharmacology of Gilles de la Tourette's syndrome. Neurosci Biobehav Rev12: 295-305
88.
Meuldijk R., Colon E.J. (1992) Methadone treatment of Tourette's disorder (letter) . Am J Psychiatr149: 139-140
89.
Mora F., Porras A. (1993) Effects of amphetamine on the release of excitatory amino acid neurotransmitters in the basal ganglia of the conscious rat. Can J Physiol Pharmacol71: 5-6
90.
Morin D., Sapena R., Zini R., Tillement J-P. (1992) Serotonin enhances the β-adrenergic response in rat brain cortical slices. Eur J Pharmacol Mol Pharmacol Sec225: 273-274
91.
Muller N., Putz A., Klages U., Hofschuster E., Straube A., Ackenheil M. (1994) Blunted growth hormone response to clonidine in Gilles de la Tourette syndrome. Psychoneuroendocrinology19: 335-341
92.
Olianas M.C., Onabi P., Neff H.N., Costa E. (1983) Adenylate cyclase activity of synaptic membranes from rat striatum. Mol Pharmacol23: 393-398
93.
Palfreyman M.G., Schmidt C.J., Sorensen S.M., Dudley M.W., Kehne J.H., Moser P., Gittos M.W., Carr A.A. (1993) Electrophysiological, biochemical and behavioural evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology112: S60-S67
94.
Paterson I.A., Juorio A.V., Boulton A.A. (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem55: 1827-1837
95.
Peroutka S.J. (1988) 5-Hydroxytryptamine receptor subtypes. Ann Rev Neurosci11: 45-60
96.
Peterson B., Leckman J.F., Scahill L., Naftolin F., Keefe D., Charest N.J., Cohen D.J. (1992) Steroid hormones and CNS sexual dimorphisms modulate symptom expression in Tourette's syndrome. Psychoneuroendocrinology17: 553-563
97.
Pitman R.K., Green R.C., Jenike M.A., Mesulam M.M. (1987) Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatr144: 1166-1171
98.
Quirion R., Gaudrea P., Martel J.C., St. Pierre S., Zamir N. (1985) Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra. Brain Res331: 358-362
99.
Rabey J.M., Lewis A., Graff E., Korczyn A.D. (1992) Decreased 3H-quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette syndrome. Biol Psychiatr31: 889-895
100.
Regeur L., Werdelin L., Pakkenberg H., Fog R. ( 1994) Pharmacological treatment of Gilles de la Tourette's syndrome . CNS Drugs2: 191-198
101.
Reveley M.A., Bird R., Stirton R.F., Dursun S.M. (1994) Microstructural analysis of the symptoms of Tourette's syndrome and the effects of a trial use of transdermal nicotine patch. J Psychopharmacol Suppl. A30: 117
102.
Robertson M.M. (1989) The Gilles de la Tourette syndrome: the current status. Br J Psychiatr154: 147-169
103.
Robertson M.M., Trimble M.R., Lees A.J. (1988) The psychopathology of Gilles de la Tourette syndrome: a phenomenological analysis. Br J Psychiatr152: 383-390
104.
Robertson M.M., Schnieden V., Lees A. ( 1990) Management of Gilles de la Tourette syndrome using sulpiride . Clin Neuropharmacol13: 229-235
105.
Rogeness G.A., Javars M.A., Pliszka S.R. (1992) Neurochemistry and child and adolescent psychiatry . J Am Acad Child Adolesc Psychiatr31: 765-781
106.
Ross M.S., Moldofsky H. (1978) A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatr1: 103-111
107.
Sandor P. (1993) Invited review—Gilles de la Tourette syndrome: a neuropsychiatric disorder. J Psychosom Res37: 211-226
108.
Sandyk R. (1985) The effects of naloxone in Tourette's syndrome . Ann Neurol18: 367-368
109.
Scatton B., Bartholini G. (1982) γ-Aminobutyric acid (GABA) receptor stimulation (IV). Effects of progabide (LS 76002) and other GABAergic agents on acetylcholine turnover in rat brain areas. J Pharmacol Exp Ther220: 689-695
110.
Scatton B., Zivkovic B., Dedek J., Lloyd K.G., Constantinidis J., Tissot R., Bartholini G. (1982) γ-Aminobutyric acid (GABA) receptor stimulation (III). Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine . J Pharmacol Exp Ther220: 678-688
111.
Schmidt C.J., Sullivan C.K., Fadayel G.M. (1994) Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine . J Neurochem62: 1382-1389
112.
Schoffelmeer A N M, Hansen H.A., Stoff J.C., Mulder A.H. (1986) Blockade of the D2 dopamine receptors strongly enhances the potency of enkephalins to inhibit dopamine-sensitive adenylate cyclase in rat neostriatum: involvement of σ-and μ-opioid receptors . J Neurosci6: 2235-2239
Shapiro A.K., Shapiro E., Sweet R.D. (1981) Treatment of tics and Tourette syndrome. In Barbeau A (ed.), Disorders of movement. J B Lippincott, Philadelphia, PA, pp. 105-132
115.
Shapiro E.S., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J., Phillips, R.A. (1989) Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatr46: 722-730
116.
Shea P.A., Wade S.E., Dunlop S.D., Hendrie H.G. (1984) Effect of chronic haloperidol on the levels of blood and urinary phenylethylamine and phenylacetic acid in rats. In Boulton A A, Baker G B, Dewhurst W G, Sandler M (eds), Neurobiology of the trace amines. Humana Press, Clifton, NJ , pp. 271-276
117.
Silver A.A., Sanberg P.R. (1993) Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet342: 182
118.
Singer H.S. (1992) Neurochemical analysis of postmortem cortical and striatal brain tissue in patients with Tourette syndrome. In Chase TN, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 135-144
119.
Singer H.S., Walkup J.T. (1991) Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. Medicine70: 15-32
120.
Singer H.S., Butler I.J., Tune L.E., Seifert W.E., Coyle J.T. (1982) Dopaminergic dysfunction in Tourette syndrome. Ann Neurol12: 361-366
121.
Singer H.S., Oshida L., Coyle J.T. (1984) CSF cholinesterase activity in Gilles de la Tourette's syndrome. Arch Neurol41: 756-757
122.
Singer H.S., Hahn I-H., Korwiak E., Nelson E., Moran T. (1990) Tourette syndrome: a neurochemical analysis of postmortem cortical brain tissue. Ann Neurol27: 443-446
123.
Singer H.S., Hahn I-H., Moran T.H. (1991) Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette syndrome. Ann Neurol30: 558-562
124.
Singer H.S., Wong D.F., Brown J.E., Brandt J., Krafft L., Shaya E., Dannals R.F., Wagner H.N. Jr (1992) Positron emission tomography evaluation of dopamine D2 receptors in adults with Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 233-239
125.
Spiegel R. (1984) Effects of RS-86, an orally active cholinergic agonist, on sleep in man. Psychiatr Res11: 1-13
126.
Stahl S.M., Berger P.A. (1981) Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. Am J Psychiatr138: 240-242
127.
Suchowersky O. (1994) Gilles de la Tourette syndrome. Can J Neurol Sci21: 48-52
128.
Sweeney D., Pickar D., Redmond D.E., Maas J. ( 1978) Noradrenergic and dopaminergic mechanisms in Gilles de la Tourette's syndrome. Lanceti: 872
129.
Sweet R.D., Brunn R.D., Shapiro E., Shapiro A.K. (1974) Presynaptic catecholamine antagonists as treatment for Tourette's syndrome: effects of α-methyl-para-tyrosine and tetrabenazine . Arch Gen Psychiatr31: 857-861
130.
Turjanski N., Sawle G.V., Playford E.D., Weeks R., Lammerstma A.A., Lees A.J., Brooks D.J. (1994) PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatr57: 688-692
